Drug Discovery World

APRIL 17, 2024

What are the challenges of drug discovery in this area? One of the great things about ASOs are that they create the most optimal binding possible between the drug and the target. It had been known for decades that TFs, which orchestrate a cell’s gene expression programs, bind to DNA and proteins.

Gene Expression 59

Gene Expression Gene Genetic Disease RNA 59

The Pharma Data

JUNE 28, 2021

Bayer’s acquisition of Noria and PSMA Therapeutics, which have nurtured Dr. Babich’s radiopharmaceutical and diagnostic technology, is an important milestone in drug development, and we look forward to the advances this collaboration can make to enhance prostate cancer therapies.”.

Licensing 52

Licensing Licensing Medicine Development 52

Drug Discovery World

JUNE 5, 2023

New approaches to partnering In this event in the Biotech track, Clive Cookson, Science Editor at the Financial Times, interviewed John McDonald, Corporate Vice President, Global R&D Business Development, Novo Nordisk. The discussion answered three main questions: What is the new direction for the company?

Genome 52

Genome Genomics Life Science Genetics 52

pharmaphorum

MARCH 8, 2022

Our products are used primarily in the fight against cancer – to aid drug discovery – while also ensuring patients and laboratory workers are safe. Darina Shopova is design engineer at Envair Technology, working on the design and development of rigid isolators. A videh Nazeri.

Life Science 98

Life Science Engineer Scientist Doctors 98

Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. million price point per dose.

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

The Pharma Data

AUGUST 3, 2021

Revenue growth was 12 percent when excluding effects of 2020 COVID-related stocking patterns, revenue from COVID-19 antibodies and recent business development. Business Development/Other Developments. In the second quarter of 2021, the company recognized acquired in-process research and development charges of $25.0

Antibody 52

Antibody Sales Development Production 52

Drug Discovery World

MAY 16, 2023

Lentiviral vectors demand Naiara Tejados, Head of Marketing and Technology Development at VIVEbiotech & Natalia Elizalde, Chief Business Development Officer at VIVEbiotech, anticipate that 2023 will be a very good year for VIVEbiotech, due to the increasing demand for lentiviral vectors.

Gene Therapy 52

Gene Therapy Gene Manufacturing Marketing 52

Drug Discovery World

NOVEMBER 9, 2023

The first three include: Sungjin Park, PhD, CEO, Onegene Biotechnology, on: ‘UniStac: Enzyme-mediated conjugation technology for accelerated development of tetraspecific NASH drug’. Klaus Wagenbauer, PhD, Founder & CEO, Plectonic, on: ‘Programmable DNA-origami-based T cell engagers: PTE’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

XTalks

AUGUST 2, 2023

They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. billion the drug generated in 2021. Pfizer’s total global revenue in 2022 from Comirnaty was $37.81

Sales 98

Sales Manufacturing FDA Approval Life Science 98

Drug Discovery World

NOVEMBER 30, 2023

Lightcast is developing a novel, programmable microfluidic platform that allows precise and highly flexible control of individual microdroplets using software-generated light patterns. To demonstrate the utility of the company’s SYNTAX system in gene assembly, the 1.7 kb Influenza A hemagglutinin gene was used as a model system.

Antibody 59

Antibody Protein Engineer In-Vivo 59

Drug Discovery World

NOVEMBER 13, 2023

Oliver Hartley, PhD, Vice President, Drug Discovery, Orion Biotechnology, on: ‘Targeting small protein GPCRs by engineering their natural ligands’. Yuchih Lin, Doctor, Sino Biological Europe, on: ‘Accelerating drug discovery using advanced antibody development platforms’.

Protein 59

Protein Antibody Engineer Scientist 59

The Pharma Data

OCTOBER 26, 2020

The FDA has granted V181, the company’s investigational dengue vaccine in Phase 1 development, Fast Track designation. Business Developments. The FDA has granted V181, the company’s investigational dengue vaccine in Phase 1 development, Fast Track designation. Organon & Co.

Sales 40

Sales Vaccination Vaccine Production 40

XTalks

OCTOBER 1, 2020

Xtalks spoke with WeiQi Lin, MD, PhD, executive vice president, research & development, and principal scientist at DURECT Corporation — a company focused on developing drugs and drug delivery methods in therapeutic areas with significant unmet need — about her transition from academia to industry. Key Moments.

Scientist 52

Scientist In-Vitro Research Life Science 52